Spanish biotech KeyZell is aiming for €5m in funding to conduct a human clinical trial for its novel brain cancer treatment.
Based on company founder Dr.Nabil Hajji’s research on cellular apoptosis induced by cell receptor blockage, the start-up will also use the investment to improve its AI system to personalise treatment for each cancer patient.
Collaborating with peers from the universities of Seville and Harvard, Hajji has succeeded in eliminating the most aggressive brain cancer, glioblastoma, following 20 years with no advances in this field.
Having earlier secured €450k in a private placement, KeyZell plans to finance the primary clinical trial in Australia with a further one in Mexico. The firm is also in negotiation with regulators in Europe, US, UK, Thailand, South Africa, Morocco and Canada.
CEO Jose del Coral says: “We created KeyZell with the objective of developing new cancer solutions and tools that can help both medical professionals and patients in their fight against this disease. This financing round will allow us to achieve our ambitious objective.”
Digital twins set to advance stroke care
Can AI help keep the human experience in social care?
mRNA discovery paves the way to safer vaccines
Eye scans provide crucial insights into kidney health
Key tips for accelerating the health security compliance journey
Nordic Consulting strengthens team in Ireland
Healthcare innovators and leaders honoured at Imprivata HealthCon user group and awards ceremony
Wearable communication system may reduce digital health divide
Molecule trains the immune system to prevent cancer
Diabetes patients urged to use fitness games with caution
- News3 weeks ago
National first for openEHR portal and e-referrals solution
- Medtech4 days ago
eSight: “The technology has the potential to change someone’s life”
- News4 weeks ago
How could technology better support patient experience in the NHS?
- Entrepreneurship2 weeks ago
‘I was producing addicts every week’ – the doctor-turned-tech leader taking on the opioid crisis